CapForce IBD 50 ETF (FFTY) Dividend Yield, History & Forecast

CapForce IBD 50 ETF (FFTY) is an exchange-traded fund (ETF) listed on the New York Stock Exchange Arca. It pays a current dividend yield of 1.50% ($0.47 per share annually (TTM)). The most recent ex-dividend date was December 31, 2025, with payment scheduled for January 2, 2026. market capitalization is approximately $75M. Review FFTY dividend history on this scorecard, compare peers in the Compare Dividend Returns tool, or project income with the dividend calculator.

FFTY fund composition

FFTY holds 52 positions, with 36.9% of assets in its ten largest. It charges an expense ratio of 0.80%, and manages $57.0M.

Top 10 holdings

HoldingWeight
CDNACareDx Inc4.69%
LIFEEthos Technologies Inc3.80%
DAVEDave Inc3.63%
NTRANatera Inc3.58%
KNSAKiniksa Pharmaceuticals International Plc3.58%
EROERO Copper Corp3.55%
WTWisdomTree Inc3.55%
ZETAZeta Global Holdings Corp3.54%
PAYSPaysign Inc3.51%
TVTXTravere Therapeutics Inc3.47%

Sector allocation

Technology36.3%Energy33.0%Healthcare15.5%Industrials13.2%Consumer Cyclical7.4%Financial Services3.4%Consumer Defensive2.4%Basic Materials2.3%Other5.1%

Frequently Asked Questions about CapForce IBD 50 ETF (FFTY)

What is CapForce IBD 50 ETF's dividend yield?
CapForce IBD 50 ETF (FFTY) pays a current trailing twelve-month dividend yield of 1.50%, which works out to $0.47 per share annually based on the most recent payout schedule.
When does CapForce IBD 50 ETF pay distributions?
The most recent ex-dividend date was December 31, 2025. The next scheduled dividend payment date is January 2, 2026.
How many years has CapForce IBD 50 ETF increased its dividend?
CapForce IBD 50 ETF (FFTY) has increased its dividend for 2 consecutive years.
What does CapForce IBD 50 ETF invest in?
The CapForce IBD 50 ETF is designed to mirror the performance outcomes of the IBD 50 Index. Developed by Investor's Business Daily as its signature investment vehicle, the IBD 50 provides access to U.S. large and mid-sized companies that display robust earnings growth alongside strong stock price appreciation. This fund implements a consistent, systematic methodology to pinpoint stocks that align with its established leadership standards.